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In order to develop preclinical models of malignant astrocytomas and oligodendrogliomas, a series of 54 resected gliomas (37 from
oligodendroglial lineage and 17 from astrocytic lineage) were xenografted subcutaneously into nude mice. Molecular alterations
commonly observed in gliomas subtypes, including LOH 1p and 1q, LOH 19q, LOH 10p and 10q, LOH 9p, TP53 and PTEN
mutations, EGFR amplification, CDKN2A homozygous deletion and telomerase reactivation were systematically screened in the
original and xenografted tumours.
In all, 23 gliomas grew in nude mice. The most anaplastic tumours were selected as shown by pathological and molecular studies of
the original tumour as well as shorter survival in patients whose tumours were successfully grafted. Comparison between the two
growth profiles showed that 10q LOH and EGFR amplification gave a tumorigenic advantage. With a few exceptions, the genetic
pattern was remarkably stable before and after growth in nude mice.
These results suggest that subcutaneous xenografts are useful and reproducible models to analyse the molecular profile of malignant
astrocytoma and oligodendroglioma. This represents the first step to improve our understanding of the correlations between
molecular alterations and response to standard or experimental therapies.
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Over the last decade, important advances have been made in the
understanding of the molecular pathways involved in the
progression of astrocytomas and oligodendrogliomas (Louis et al,
2001). Recent data also suggest that acquired genetic alterations,
such as LOH 1p–19q, could be important predictors of prognosis
and response to therapy (Cairncross et al, 1998; Smith et al, 2000;
Ino et al, 2001). Unfortunately, the lack of clinically relevant
models of gliomas seriously affects fine analysis of the correlation
between genotype and treatment response. This is particularly
clear for oligodendrogliomas, which are very difficult to maintain
in in vitro cultures (Merrill and Matsushima, 1988; Post and
Dawson, 1992; McLaurin et al, 1995). In this setting, well-
characterised xenografts of gliomas could be of help, as specified
by the recommendations of the European Medicines Evaluation
Agency (EAEMP, 1999) and the EORTC Laboratory Research
Division (EORTC LRD, 2001). However, it remains to be
demonstrated that astrocytic and oligodendroglial tumours can
grow reproducibly in nude mice while maintaining the same
profile of genetic alterations as in the original tumour.
MATERIAL AND METHODS
Tumour classification
A set of 54 gliomas was surgically resected at the Pitie ´-Salpe ˆtrie `re
hospital, Paris and the Centre Hospitalier Re ´gional, Nancy. An
informed consent was obtained for all patients. After pathological
review according to the current WHO guidelines (MK) (Kleihues
and Cavenee, 2000), except for the addition of a recently
individualised subgroup of glioblastoma with an oligodendroglial
component (GBMO) (He et al, 2001), the tumours were classified
as oligodendroglioma (one O), mixed gliomas (two OA), anaplastic
oligodendroglioma (29 AO), anaplastic oligoastrocytoma (one
AOA), four GBMO and finally a subset of 17 glioblastoma (GBM)
that was used as a control group.
Xenograft protocol
Each tumour was xenografted subcutaneously into the scapular
area. Following a maximal delay of 2h after surgical resection,
small fragments (B50mm
3) of tumour tissue were xenografted
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sonto at least three anaesthetised nude mice (Swiss nu/nu) aged 6–8
weeks. Before xenograft, tumours were kept in foetal calf serum-
free DMEM (Sigma-Aldrich, St Louis, MO, USA). The mice were
maintained under clean room conditions and received sterile
rodent food and water ad libitum. Their care and housing were in
accordance with institutional guidelines as put forth by the
Ministe `re de l’Agriculture et de la Fore ˆt, Direction de la Sante ´ et de
la Protection Animale, Paris, France and the standards required by
the UKCCCR guidelines (Workman et al, 1998).
The mice were kept alive for a maximum of 12 months until the
growth of the xenografts. The tumours were measured once a week
in two perpendicular dimensions and their volumes were
estimated using the formula (width)
2 (length)/2. Latency was
defined as the time between first transplantation and the
appearance of a palpable tumour. The doubling time was
calculated once it became stable, that is, usually after the fifth
passage. The mice were killed when the tumour volume reached
2000mm
3 and the xenografts were maintained by serial transplan-
tation.
DNA EXTRACTION
Paired blood and tumours could be obtained for 31 initial
tumours, blood could not be obtained for 12 tumours, and
unfortunately tumour samples were not fresh frozen in 11 cases.
Blood DNA was extracted using the Nucleon BACC3 DNA
Extraction kit (Amersham Bioscience, Piscataway, NJ, USA) and
tumoral DNA was extracted using the QIAamp DNA minikit, as
described by the manufacturer (Qiagen, Venlo, NL, USA).
Microsatellite analysis for loss of heterozygosity (LOH) on
chromosomes 1, 9p, 10 and 19q
Blood and tumour DNA were screened for LOH on chromosome
1p, using the following polymorphic markers: D1S450, D1S2667,
D1S234, D1S255, D1S2797, D1S2890, on chromosome 1q using
D1S2878, D1S249, D1S2785 markers. On chromosome 9p LOH was
screened, using the following markers: D9S286, D9S168, D9S1870,
D9S156, D9S1687, spanning the region located near CDKN2A. On
chromosome 10p, LOH was screened using the following markers:
D10S249, D10S189, D10S547 (near hTR repressor), D10S585 (near
hTR repressor), D10S548, D10S204, on chromosome 10q using
D10S537, D10S219, D10S1744 (near PTEN), D10S541, D10S579,
D10S1755, D10S1671, D10S597, D10S1693, D10S209, D10S587
(near DMBT1), D10S1723, D10S212, D10S537, D10S541, D10S597,
D10S1693, D10S212 markers spanning the region located between
10q21.22 and 10qter. And for chromosome 19q, LOH was screened
using the following markers: D19S425, D19S219, D19S888,
D19S412, D19S418. One of the primers was labelled with the
Hex, Fam or Ned fluorochromes (Applied Biosystems, Foster City,
CA, USA). The samples were run on an automatic sequencer and
analysed with the Gene Scan program (Applied Biosystems, Foster
City, CA, USA).
Screening of the PTEN/MMAC1 and TP53 gene mutations
PTEN/MMAC1 mutations were screened by the denaturing
gradient gel electrophoresis (DGGE) technique in the entire coding
sequence of the nine exons and their corresponding splice
junctions using previously described primers (Zhou et al, 1999).
TP53 mutations were screened by the DGGE technique for exons
5–8 and their using previously described primers (Hamelin et al,
1994). DNA showing altered DGGE profiles were sequenced
bidirectionally using the Perkin Kit and sequencer. When a DNA
variant was found, the corresponding blood DNA was sequenced
in order to differentiate somatic events from constitutional
variants (polymorphism or germline mutation).
Screening of EGFR gene amplification and P16/CDKN2A
gene homozygous deletion
EGFR amplification was screened by semiquantitative PCR using
primers and protocol described previously (Hunter et al, 1995).
P16/CDKN2A homozygous deletions were screened by semiquan-
titative PCR using primers and protocol previously described
(Walker et al, 1995).
Screening of telomerase activity
Telomerase activity was screened by Telomeric Repeat Amplifica-
tion Protocol (TRAP) technique using the TRAPeze kit (Intergen
Co, Purchase, NY, USA) as described by the manufacturer.
Statistical. analyses
Descriptive statistics for continuous variates are provided as mean,
standard deviation, median, minimum and maximum. For
categorical variates, frequency distribution, median, minimum
and maximum are provided.
The relation between categorical variates is described using the
w
2 method, or Fisher’s exact test when the w
2 method is not
appropriate.
Prognostic factors for tumour growth delay are identified using
univariate analysis (log rank test) and multivariate analysis fitting
Cox’s proportional hazard regression models. All tests are
considered significant at the 0.05 significance level. Odds ratios
are presented with their 95% confidence interval.
Analyses were performed using the SAS/STAT software v8.0
(SAS Institute, Inc., Cary, NC, USA).
RESULTS
Patient characteristics and relationship with tumour
growth
The 54 surgical samples were obtained from 33 men and 21
women, with a median age of 57. 4 years (range 20–77). The post-
op median survival was 11.03 months after a median follow-up of
31.9 months (range 1–37.2).
Figure 1 Representative histology of two tumours before and after
xenograft on nude mice. (A) GIR in situ tumour, anaplastic oligoden-
droglioma morphology, haematoxylin–eosin HE staining (magnification
 200); (B) ODA-17-GIR corresponding xenograft, passage 1, dediffer-
entiated morphology, HE staining ( 400); (C) ROM in situ tumour, GBM
histology, haematoxylin–eosin (HE) staining ( 200); (D) GBM-7-ROM
corresponding xenograft, passage 3, dedifferentiated morphology, HE
staining ( 400).
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sOut of 54 tumours, 23 were established in nude mice (42.2%). In
total, 14 were derived from oligodendroglial tumours (one AOA,
nine AO, four GBMO) and nine from GBM. When a tumour was
tumorigenic, it grew on at least 60% of mice at the first
transplantation and on 80–100% mice on later transplantations.
None of the three low-grade gliomas were established in nude
mice, while 23 out of 51 high-grade gliomas did (45%).
Out of 21 grade IV gliomas, 13 were established in nude mice
(62%), while 10 out of 30 grade III did (33%) (P¼0.0047).
Patients, whose tumours did not grow had a longer survival
(14.9 months) (range 1.4–37.2) than those whose tumour could be
established (9.1 months) (range 0.2–32.5) (P¼0.0003).
Histology after xenograft
After xenograft in nude mice, tumours presented a dedifferentiated
phenotype devoid of any particular pattern with small round or
fusiform cells. Grafted oligodendrogliomas displayed a complete
loss of ‘honeycomb’ appearance (Figure 1B, D). The cellular
density was very high. Neither endothelial hyperplasia nor
endothelial proliferation could be observed. Many mitotic and
apoptotic figures were seen in the same samples, while central
areas of necrosis were almost constant. Tumours lost their glial
differentiation whatever their initial type (oligodendroglial or
astrocytic), except one tumour with an initial morphology of
mixed anaplastic glioma, which exhibited an oligo-like differentia-
tion after xenograft (ABE).
Genetic alterations of primary tumours and relationship
with tumour growth
As summarised in Table 1, screening for p53 mutations, PTEN
mutations, EGFR amplifications and p16/INK4a homozygous
deletions was performed in 43 tumours. Screening for LOH on




Tumour P Q Q P P Q TP53 PTEN EGFR CDKN2A Telomerase activity
(a)
VIL LOH LOH LOH LOH LOH LOH — — amp hd ND
RAV LOH LOH — — LOH LOH mut — amp — Present
RAI LOH LOH LOH — LOH — mut — — — Absent
GEN LOH — LOH LOH LOH LOH — — amp hd Present
MEG LOH — LOH — LOH LOH — — — — ND
THO — — LOH LOH LOH LOH mut mut — — Absent
PID — — LOH — LOH LOH — — — hd ND
VIB — — — LOH LOH LOH — mut — hd ND
BAS — — — — LOH LOH — — — — ND
IOC — — — LOH LOH — — — — — ND
MAA — — — — — — — amp — ND
B O B —— — ——— — — — — N D
C A R —— — ———m u t — — — N D
KNO — — — — LOH LOH — — — — ND
GIR — — — — LOH LOH — — amp hd Present
CHA — — — LOH LOH LOH — mut — hd Present
HAA — — — LOH LOH LOH mut mut — hd Present
ROM — — — — LOH LOH — — — — Present
JEU ND ND ND ND ND ND — — amp hd Present
(b)
ABD LOH — LOH LOH — LOH — — — hd Absent
AMR LOH — LOH LOH — LOH — — — hd Present
HAN LOH — LOH LOH LOH LOH — — — — Absent
DUR LOH LOH LOH — — — mut — — — Absent
MAT LOH — LOH — — — — — — — Present
PER LOH — LOH LOH — — — — — — Absent
ROU LOH — LOH — — — — — — — Present
LAL — LOH — — LOH LOH — mut — — Present
GUI — — — — LOH LOH mut — — — Present
BEU — — — LOH LOH LOH — — — — Absent
JAN — — — — — — mut — — — Absent
BOS — — — — LOH — — — — — Absent
YBE — — — — — — — — — hd Absent
BAY ND ND ND ND ND ND — — — — ND
DOR ND ND ND ND ND ND — — — — ND
H A D N DN D N D N DN DN D — — — — N D
LEB ND ND ND ND ND ND mut — — — ND
L O S N DN D N D N DN DN D — — — — N D
M A S N DN D N D N DN DN D — — — — N D
PET ND ND ND ND ND ND — — — — ND
PIG ND ND ND ND ND ND — — — hd ND
P O U N DN D N D N DN DN D — — — — N D
VAU ND ND ND ND ND ND — — — — ND
Z A Y N DN D N D N DN DN D — m u t — h d N D
(a) Established tumours; (b) nonestablished tumours; LOH ¼ loss of heterozygosity; mut ¼ mutation; amp ¼ genomic amplification; hd ¼ homozygous deletion; ND ¼ not
done.
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schromosomes 1p, 1q, 19q, 10p, 10q, 9p was performed for 31
tumours and for telomerase activity in 22 tumours.
Tumours were separated into two groups. The first one
consisted of tumours that grew in nude mice for at least two
transplantations (n¼19) and the second group of those that did
not (n¼24). Comparison of the two groups showed that growth in
nude mice was correlated to 10q LOH and EGFR amplification
(P¼0.01 and 0.0035, respectively). In addition, when genetic
alterations linked to anaplasia were pooled (chromosome 10 loss,
chromosome 9p loss, EGFR amplification, p16 deletion, PTEN
mutation and telomerase reactivation), nongrowing tumours
showed significantly fewer alterations than growing tumours
(P¼0.029). Among the whole series, no alteration could be
correlated to a nontumorigenic feature.
Genetic alterations after establishment in nude mice
Comparison of genetic alterations was made between primary
tumours (at the time of surgery) and first transplantations in nude
mice, and then between the first and subsequent transplantations.
Tumours showed a striking genetic stability before and after
establishment in mice (Table 2). No alteration disappeared after
xenograft and only two new alterations appeared in xenografts (a
1p loss for ODA-4-GEN and a PTEN homozygous deletion for
ODA-20-THO). After the first transplantation, the molecular
profile of alterations remained constant.
Correlations between spontaneous growth rate and genetic
alterations
The latency (time between the first transplantation and the
appearance of a palpable tumour) and the doubling time for 12
growing tumours are summarised in Table 3 showing that even if
latency differed between tumours, the doubling time remained
relatively stable. For the different genetic alterations tested,
multivariate analysis showed that only EGFR amplification was
associated with a higher growth rate (P¼0.0082).
DISCUSSION
These data indicate that human xenografts are useful models to
study the molecular pathways involved in malignant oligoden-
drogliomas and astrocytomas. However, successful grafting
occurred only in anaplastic tumours in terms of pathological
grading of the original tumours, genotype analysis and prognostic
significance for donor patients.
None of the grafted low-grade gliomas grew on nude mice while
(45%) 23/51 high-grade gliomas did. Even among malignant
gliomas, there was a significant difference, suggesting that higher
grade tumours were preferentially selected by the grafting process
since 62% (13/21) GBM or GBMO (grade IV) grew as compared to
33% (10/30) AO, AOA (grade III) (P¼0.0047).
The results of the molecular analysis of the primary tumour
(before grafting) are in agreement with the pathological data.
Overall, growing tumours had significantly more molecular
alterations than the nongrowing ones. This finding is particularly
striking for EGFR amplification and LOH on chromosome 10, two
alterations highly associated with increased malignancy (Bigner
and Vogelstein, 1990; von Deimling et al, 1992; Reifenberger et al,
1996). It has previously been shown that EGFR amplification gives
a tumorigenic advantage in GBM (Humphrey et al, 1988; Muleris
et al, 1994), a feature that we often found associated with stable
double-minute extra-chromosomal elements on caryotypic analy-




Tumour P Q Q P P Q TP53 PTEN EGFR CDKN2A Telomerase activity
RAI LOH LOH LOH — LOH — mut — — — Absent
ODA-5-RAI p1 LOH LOH LOH — LOH — mut — — — Absent
ODA-5-RAI p4 LOH LOH LOH — LOH — mut — — — Absent
RAV LOH LOH — — LOH LOH mut — amp — Present
ODA-14-RAV p1 LOH LOH — — LOH LOH mut — amp — Present
ODA-14-RAV p13 LOH LOH — — LOH LOH mut — amp — Present
GEN — — LOH LOH LOH LOH amp hd Present
ODA-4-GEN p1 LOH — LOH LOH LOH LOH — — amp hd Present
ODA-4-GEN p7 LOH — LOH LOH LOH LOH — — amp hd Present
THO — — LOH LOH — LOH mut — — — Absent
ODA-20-THO p1 — — LOH LOH — LOH mut hd — — Absent
ODA-20-THO p6 — — LOH LOH — LOH mut hd — — Absent
RAI, RAV, GEN, THO ¼ initial tumours. ODA-4-GEN, ODA-14-RAV, ODA-4-GEN, ODA-20-THO ¼ xenografted tumours; px ¼ passage X; LOH ¼ loss of heterozygosity;
mut ¼ mutation; amp ¼ genomic amplification; hd ¼ homozygous deletion; ND ¼ not done.
Table 3 Growth characteristics of xenografts















(a) Oligodendroglial xenografts; (b) GBM xenografts. Latency was measured between
graft and appearance of a palpable tumour at the first transplantation. Doubling time
was measured when it became stable, after passage 5.
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ssis (data not shown) (Bigner et al, 1989). In addition, EGFR
amplification was present in 4/11 successfully grafted oligoden-
drogliomas in our series, indicating that the tumorigenic role of
this alteration affects various subtypes of gliomas. Interestingly,
overexpression of EGFR in transgenic mice has been shown to be
involved in tumour progression of oligodendroglioma (Ding et al,
2003).
Similarly, we found that LOH on chromosome 10 was also
extremely frequent not only in GBM (100%, 7 out of 7) but also in
growing oligodendrogliomas (73%, eight out of 11). Thus, the loss
of the putative tumour suppressor gene located on chromosome 10
is important for tumorigenicity in both tumour subtypes.
However, we did not find evidence of involvement of the PTEN
gene, which is located on chromosome10, in this series.
The fact that pathological and molecular factors predictive of
successful grafting were associated with higher malignancy
explaining that survival was shorter in donor patients whose
tumours grew in nude mice (9.1 months) as compared to survival
of patients whose tumours were rejected (15.4 months)
(P¼0.0003).
An important characteristic of this model is the stability of the
genetic alterations in the xenografts as compared to the primary
tumours, a finding also observed after successive passages in nude
mice. Such stability, which was somewhat controversial in previous
studies (Bigner et al, 1989; Muleris et al, 1994; Goike et al, 1999;
Jeuken et al, 2000), appears to hold both for GBM and anaplastic
oligodendrogliomas. Nevertheless, rare differences before and after
growth on nude mice were shown as illustrated in Table 2. Rather
than selection of a minor subclone, it is likely, as shown in Figure 2,
that these alterations were already present in the original tumour,
but were hardly visible or even undetectable because of the
presence of ‘contaminating’ normal tissue.
An advantage of this model is therefore to obtain tumours
devoid of normal cells, improving the quality of molecular analyses
(Figure 2).
Despite a stable genetic profile, the phenotype of the grafted
tumour cells underwent striking changes whatever the histological
features of the original tumour. After xenograft, all but one glioma
lost their glial differentiation and presented a dedifferentiated
phenotype in contrast with xenografts derived from other human
cancers that maintained several of their histological characteristics
(Rofstad et al, 1990a,b; Poupon et al, 1993; Kolfschoten et al, 2000;
Bras-Goncalves et al, 2001; de Pinieux et al, 2001; Krasagakis et al,
2001).
Whether the morphological homogeneity of grafted tumours
represents a nonspecific change or supports the view that many
gliomas have a common cell of origin (Daumas-Duport et al, 1997)
leading to various morphological appearance in patients remains
unsettled.
In summary, xenografting malignant astrocytomas and oligo-
dendrogliomas is a useful method for studying and probably
refining knowledge of the spectrum of genetic alterations in these
tumours. This method can be of help in analysing the correlations
between genotype and response to chemotherapy or various
experimental agents. In addition, it may further benefit from new
approaches such as gene expression by microarray studies in order
to identify genes associated with chemosensitivity.
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